OMEROMEROS CORP
Pharmaceutical Preparations
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$122M
- 27% YoY
- Market cap
- $1.3B
- Employees
- 175
- Net debt / EBITDA
- —
- $71M net debt
- AI in 10-K
- 1.7
- mentions per 10K words
Takeover score 3 of 13
Fixable underperformance 2 of 7
- TSR below peersNo—3+ of last 5 years
- High CEO pay despite TSRNo—Median CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo—Cash flow under 80% of net income
- Dilutive SBCYes11% of revenueOver 10% of revenue
- Payouts exceed cash flowNo0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyNo—Over 40% of assets
- Shareholder dissentYes78% lowest supportAny vote under 80% support
Buyer economics 1 of 4
- Low revenue per employeeNo$422K · 51st pctBottom quartile of its SIC industry
- Quiet on AINo1.7 per 10K words · 51st pctBottom quartile of AI mentions in 10-Ks
- Net cashNo—More cash than debt, positive EBITDA
- Buyout-sizedYes$1.3B market capMarket cap $500M–$5B
Catalysts 0 of 2
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingNo−$3M netNet sales over $10M in 12 months
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Operating income | −$174M | −$163M | −$165M | −$167M | −$123M | 26% |
| Net income | $194M | $47M | −$118M | −$157M | −$3M | 98% |
| Operating cash flow | −$110M | −$86M | $75M | −$149M | −$116M | 22% |
| Capex | $277K | $113K | $426K | $165K | $65K | 61% |
| Stock-based comp | $18M | $14M | $12M | $10M | $8M | 22% |
| Buybacks | $0 | $0 | $5M | $12M | $0 | 100% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $3M · 14
- Net
- −$3M
Pay vs performance
No pay-versus-performance disclosure yet.